The resistance of PARP inhibitors was due to the lack of homology-directed DNA repair (43), and the resistance of PD1/PD-L1 is because of T cell dysfunction, antigen recognition disorders, T cell activation disorders, etc. Immune infiltration in the tumor microenvironment is a prerequisite for immunotherapy, which is affected by the variable immune cell and chemokine proportions (44). The gene discussed is PDCD1; the disease is neoplasm.